諾和諾德(Novo Nordisk) semaglutide, (GPL-1 analogue) 勝Eli Lilly Trulicity (dulaglutide)

諾和諾德糖尿病藥 減重成效更勝禮來 2017-08-17 23:05經濟日報 記者林筠╱即時報導 彭博資訊報導，製藥公司諾和諾德（Novo Nordisk A/S）證實其實驗療法semaglutide，在為糖尿病患者控制血糖以及減重方面比對手禮來藥廠的療法更有效。諾和諾德16日在聲明中表示，在名為Sustain 7的後期研究發現，患者每周接受一次semaglutide療法搭配降血糖藥metformin，療效比使用禮來的易週糖（Trulicity）更佳。諾和諾得16日股價跳升至逾七周以來最高。諾和諾德科技長湯姆森在聲明中表示，試驗結果可能有助於semaglutide成為第二型糖尿病的新標準療法。貝倫貝格銀行分析師坎普爾表示，由於禮來易週糖的美國市占率將在2017年底前超過諾和諾德的舊暢銷藥物Victoza，semaglutide在今年獲主管機關核准，已成為諾和諾德的當務之急。

New Novo Nordisk drug semaglutide outperforms Trulicity in new trial

Jack Woodfield Thu, 17 Aug 2017 Novo Nordisk has announced that semaglutide, a new GPL-1 analogue drug, outperformed Eli Lilly's equivalent Trulicity (dulaglutide) in a new trial. Semaglutide, a once-weekly blood glucose-lowering drug, led to better glucose control and enabled greater weight loss compared to Trulicity, Novo Nordisk reports. "The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire SUSTAIN programme," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes." Semaglutide is a type 2 diabetes drug which stimulates the release of insulin and suppresses glucagon, working to decrease appetite and food intake. It is currently being considered for approval by the European Medicines Agency (EMA), which grants licenses for the use of treatment across the continent.  In this new 40-week trial, 69 per cent of people with type 2 diabetes who were treated with a 0.5mg dose of semaglutide achieved their HbA1c targets compared to 52 per cent in the 0.75mg Trulicity group. Those in the 0.5mg semaglutide group had a reduction in average HbA1c of 1.5% against a 1.1% in the Trulicity group. Additionally, 1.0mg doses of semaglutide reduced average HbA1c results by 1.8%, with a decreased reduction of 1.4% noted among those treated with 1.5mg Trulicity. Results from these higher doses saw 79 per cent of people on semaglutide reach their HbA1c targets, compared to 68 per cent on Trulicity. Those on the 0.5mg semaglutide also lost an average of 4.6kg of weight compared to 2.3kg with the 0.75mg dosage of dulaglutide; the higher doses led to 6.5kg on semaglutide compared to 3.0kg on Trulicity.  Scientists said semaglutide was also safe and well-tolerated. There were side effects including sickness for both sets of dosages comparable between the two drugs, but these did subside. Less then 10 per cent of people treated in all the regimes stopped taking the drugs due to adverse events.